A group of Senate Republicans recently urged federal regulators to withdraw a plan to change the definition of a drug’s [...] …
Articles by : Tom Mirga, Editor at Large
A federal district judge in South Carolina late today struck down the 340B program’s patient definition, as federal regulators described [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
The New York State Department of Health recently told a state trial court in Manhattan that two community health centers [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Generic and biosimilar drugmaker Sandoz today became the 28th pharmaceutical company to place conditions on 340B pricing involving drug shipments [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
The recent end of a 340B program waiver for hospitals is wrong, hurts hospitals and their patients, and is bound [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
The Health Resources and Services Administration (HRSA) confirmed today it is ending a 340B program waiver issued early in the [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Genentech, Sanford Health, and Carolina Health Centers’ 340B reform group, 340B Working Table, spent $110,000 on lobbying and gained eight [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Indian biopharmaceutical manufacturer Biocon Biologics has notified 340B covered entities about a new national drug code (NDC) for insulin glargine-yfgn, [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Drug manufacturer Genentech has asked health systems and hospitals about possible 340B program compliance violations involving split-billing software settings. Staff [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Regulators are seeking input on a contractor to help it shield drug manufacturers from giving duplicate 340B discounts and new [...] …